Pluristem Therapeutics Inc (PSTI)

[surf1944]

4:30AM Pluristem Therapeutics receives approval to expand its Phase II clinical trial in intermittent claudication to Germany (PSTI) 3.24 : Co announces the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication. IC is a subset of Peripheral Artery Disease. According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of ~$2.5 bln annually to the healthcare system.